CEO and CFO buying at Theralase Technologies (TLT)

CEO and CFO buying at Theralase Technologies (V:TLT)

Roger John Dumoulin-White, CEO, Director and 10% Holder, acquired 100,000 Common Shares on a direct ownership basis, 50,000 Common Shares on an indirect ownership basis for registered holder Kyla Dumoulin-White and 50,000 Common Shares on an indirect ownership basis for registered holder Robert Dumoulin-White at a price of $0.350 through a prospectus or prospectus exempt offering on January 9th, 2019. The insider also acquired 100,000 Warrants on a direct ownership basis,  50,000 Warrants on an indirect ownership basis for registered holder Kyla Dumoulin-White and 50,000 Warrants on an indirect ownership basis for registered holder Robert Dumoulin-White with an exercise price of $0.500 for a period of 24 months. This represents a $70,000 investment into the company's shares and an account share holdings change of 3.2%.

Kristina Maria Hachey, CFO, acquired 100,000 Common Shares and 100,000 Warrants on a direct ownership basis. This represents a $35,000 investment into the company's shares and an account share holdings change of 6.9%.

Theralase Technologies is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Theralase Technologies Inc. is a biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (PDCs) to destroy cancer. The Company operates through two divisions: Therapeutic Laser Technology (TLT) division and Photo Dynamic Therapy (PDT) division. The TLT division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology is used for healing a range of nerve, muscle and joint conditions, including arthritis, osteoarthritis and wounds. The PDT division develops PDCs and activates them with laser technology to destroy specifically targeted cancers and bacteria. Its TLC-2000 Biofeedback Therapeutic Laser Technology possesses Cell Sensing technology that senses and targets injured tissue. It is also developing TLC-1000 therapeutic medical laser system. It is developing TLC-3000 medical laser system for the treatment of a range of cancers.